Advertisement

An Emerging Model for Cancer Development from a Tumor Microenvironment Perspective in Mice and Humans

  • Ryuji Yamaguchi
  • Guy Perkins
Chapter
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1225)

Abstract

In the past, cancer development was studied in terms of genetic mutations acquired in cancer cells at each stage of the development. We present an emerging model for cancer development in which the tumor microenvironment (TME) plays an integral part. In this model, the tumor development is initiated by a slowly growing nearly homogeneous colony of cancer cells that can evade detection by the cell’s innate mechanism of immunity such as natural killer (NK) cells (first stage; colonization). Subsequently, the colony develops into a tumor filled with lymphocytes and stromal cells, releasing pro-inflammatory cytokines, growth factors, and chemokines (second stage; lymphocyte infiltration). Cancer progression proceeds to a well-vesiculated silent tumor releasing no inflammatory signal, being nearly devoid of lymphocytes (third stage; silenced). Eventually some cancer cells within a tumor undertake epithelial-to-mesenchymal transition (EMT), which leads to cancer metastasis (fourth stage; EMT). If a circulating metastasized cancer cell finds a niche in a new tissue and evades detection by NK cells, it can establish a new colony in which very few stromal cells are present (fifth stage; metastasis), which is much like a colony at the first stage of development. At every stage, cancer cells influence their own TME, and in turn, the TME influences the cancer cells contained within, either by direct interaction between cancer cells and stromal cells or through exchange of cytokines. In this article, we examine clinical findings and animal experiments pertaining to this paradigm-shifting model and consider if, indeed, some aspects of cancer development are governed solely by the TME.

Keywords

Tumor microenvironment Epithelial-to-mesenchymal transition (EMT) Metastasis Natural killer cell (NK) Cancer development Malignant pleural mesothelioma (MPN) Lymphocytic infiltration Ductal carcinoma in situ (DCIS) Cancer associated fibroblast (CAF) Tumor associated macrophage (TAM) Myeloid-derived suppressor cell (MDSC) Cytokines Chemokines Pleural effusion 

Notes

Acknowledgement

We would like to thank Prof. Courtney Broaddus at the Dept. of Medicine, University of California, San Francisco, for informative discussion on MPM. The project was initiated when R.Y. was at Kansai Medical University, Hirakata, Japan.

References

  1. 1.
    Stratton MR (2011) Exploring the genomes of cancer cells: progress and promise. Science 331(March):1553–1558.  https://doi.org/10.1126/science.1204040CrossRefPubMedGoogle Scholar
  2. 2.
    Marcus A, Gowen BG, Thompson TW et al (2014) Recognition of tumors by innate immune system and natural killer cells. Adv Immunol 122:91–128  https://doi.org/10.1016/B978-0-12-800267-4.00003-1Google Scholar
  3. 3.
    Burstein HJ, Polyak K et al (2004) Ductal carcinoma in situ of the breast. N Engl J Med 350:1430–1441CrossRefGoogle Scholar
  4. 4.
    Yamaguchi R, Perkins G (2018) Animal models for studying tumor microenvironment (TME) and resistance to lymphocytic infiltration. Cancer Biol Ther 18:1–10.  https://doi.org/10.1080/15384047.2018.1470722CrossRefGoogle Scholar
  5. 5.
    Joyce JA, Fearon DT (2015) T cell exclusion, immune privilege, and the tumor microenvironment. Science 348(6230):74–80CrossRefGoogle Scholar
  6. 6.
    Yeung KT, Yang J (2017) Epithelial–mesenchymal transition in tumor metastasis. Mol Oncol 11:28–39.  https://doi.org/10.1002/1878-0261.12017CrossRefPubMedGoogle Scholar
  7. 7.
    Labelle M, Begum S, Hynes RO (2011) Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 20:576–590.  https://doi.org/10.1016/j.ccr.2011.09.009CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Hong Y, Fang F, Zhang Q (2016) Circulating tumor cell clusters: what we know and what we expect (review). Int J Oncol 49:2206–2216.  https://doi.org/10.3892/ijo.2016.3747CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Harlin H, Meng Y, Peterson AC et al (2009) Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res 69(7):3077–3086.  https://doi.org/10.1158/0008-5472.CAN-08-2281CrossRefPubMedGoogle Scholar
  10. 10.
    Gabrilovich DI (2017) Myeloid-derived suppressor cells. Cancer Immunol Res 5(1):3–9.  https://doi.org/10.1158/2326-6066.CIR-16-0297CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Malladi S, Macalinao D, Jin X et al (2016) Metastatic latency and immune evasion through autocrine inhibition of WNT article metastatic latency and immune evasion through autocrine inhibition of WNT. Cell 165:45–60.  https://doi.org/10.1016/j.cell.2016.02.025CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Tabbekh M, Franciszkiewicz K (2018) Rescue of tumor-infiltrating lymphocytes from activation-induced cell death enhances the antitumor CTL response in CD5-deficient mice. J Immunol 187:102–109.  https://doi.org/10.4049/jimmunol.1004145CrossRefGoogle Scholar
  13. 13.
    Zhou R, He P, Ren Y et al (2007) Myeloid suppressor cell-associated immune dysfunction in CSA1M fibrosarcoma tumor-bearing mice. Cancer Sci 98(6):882–889.  https://doi.org/10.1111/j.1349-7006.2007.00465.xCrossRefPubMedGoogle Scholar
  14. 14.
    Bayne LJ, Beatty GL, Jhala N, Clark CE, Rhim AD, Stanger BZ (2012) Tumor-derived granulocytes-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 21(6):822–835.  https://doi.org/10.1016/j.ccr.2012.04.025CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Pylayeva-gupta Y, Lee KE, Hajdu CH, Miller G, Bar-sagi D (2012) Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell 21(6):836–847.  https://doi.org/10.1016/j.ccr.2012.04.024CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Zhu Y, Knolhoff BL, Meyer MA et al (2014) CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res 74:5057–5070.  https://doi.org/10.1158/0008-5472.CAN-13-3723CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Strachan DC, Ruffell B, Oei Y et al (2013) CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8 T cells CSF1R inhibition delays cervical and mammary tumor growth in murine models by. Oncoimmunology 2(12):e26968.  https://doi.org/10.4161/onci.26968CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Garcia AJ, Ruscetti M, Arenzana TL, Tran LM, Bianci-frias D, Sybert E (2017) Pten null prostate epithelium promotes localized myeloid-derived suppressor cell expansion and immune suppression during tumor. Mol Cell Biol 34(11):2017–2028.  https://doi.org/10.1128/MCB.00090-14CrossRefGoogle Scholar
  19. 19.
    Pasello G, Zago G, Lunardi F et al (2018) Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical–pathological features and intratumor heterogeneity over time original article. Ann Oncol 29(March):1258–1265.  https://doi.org/10.1093/annonc/mdy086CrossRefPubMedGoogle Scholar
  20. 20.
    Fassina A, Cappellesso R, Guzzardo V et al (2011) Epithelial–mesenchymal transition in malignant mesothelioma. Mod Pathol 25(1):86–99.  https://doi.org/10.1038/modpathol.2011.144CrossRefPubMedGoogle Scholar
  21. 21.
    Hmeljak J, Sanchez-vega F, Hoadley KA et al (2018) Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov 81(12):1548–1565.  https://doi.org/10.1158/2159-8290.CD-18-0804CrossRefGoogle Scholar
  22. 22.
    Mezzapelle R, Rrapaj E, Gatti E et al (2016) Human malignant mesothelioma is recapitulated in immunocompetent BALB/c mice injected with murine AB cells. Sci Rep 6(February):22850.  https://doi.org/10.1038/srep22850CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Schwartz H, Blacher E, Amer M et al (2016) Incipient melanoma brain metastases instigate astrogliosis and neuroinflammation. Cancer Res 76(15):4359–4372.  https://doi.org/10.1158/0008-5472.CAN-16-0485CrossRefPubMedGoogle Scholar
  24. 24.
    Strachan DC, Ruffell B, Oei Y et al (2013) CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8 T cells. Oncoimmunology 2(12):e26968.  https://doi.org/10.4161/onci.26968CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Zhu Y, Knolhoff BL, Meyer MA et al (2014) CSF1/CSF1R blockade reprograms tumor-in filtrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res 74:5057–5070.  https://doi.org/10.1158/0008-5472.CAN-13-3723CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Menon H, Ramapriyan R, Cushman TR et al (1933) Role of radiation therapy in modulation of the tumor stroma and microenvironment. Front Immunol 10(February):2019.  https://doi.org/10.3389/fimmu.2019.00193CrossRefGoogle Scholar
  27. 27.
    Bernstein MB, Krishnan S, Hodge JW, Chang JY (2016) Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach? Nat Rev Clin Oncol 13(8):516–524.  https://doi.org/10.1038/nrclinonc.2016.30CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Yao ES, Zhang H, Chen Y et al (2007) Increased B1 integrin is associated with decreased survival in invasive breast cancer. Cancer Res 67(2):659–665.  https://doi.org/10.1158/0008-5472.CAN-06-2768CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Hu-lieskovan S, Mok S, Moreno BH et al (2015) Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanoma. Sci Transl Med 7(279):279ra41CrossRefGoogle Scholar
  30. 30.
    Frederick DT, Piris A, Cogdill AP et al (2013) BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res 19(5):1225–1232.  https://doi.org/10.1158/1078-0432.CCR-12-1630CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Pelster MS, Amaria RN (2019) Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials. Ther Adv Med Oncol 11:1–11.  https://doi.org/10.1177/1758835919830826CrossRefGoogle Scholar
  32. 32.
    Morgan A, Holmes A (1980) Concentrations and dimensions of coated and uncoated asbestos fibres in the human lung. Br J Ind Med 37:25–32PubMedPubMedCentralGoogle Scholar
  33. 33.
    Feder IS, Tischoff I, Theile A, Schmitz I, Merget R, Tannapfel A (2017) The asbestos fibre burden in human lungs: new insights into the chrysotile debate. Eur Respir J 49:1602534.  https://doi.org/10.1183/13993003.02534-2016CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Boylan AM, Sanan DA, Sheppard D, Broaddus VC (1995) Vitronectin enhances internalization of crocidolite asbestos by rabbit pleural mesothelial cells via the integrin avfi5. J Cli Invest 96:1987–2001CrossRefGoogle Scholar
  35. 35.
    Liu W, Ernst JD, Broaddus VC (2000) Phagocytosis of crocidolite asbestos induces oxidative stress, DNA damage, and apoptosis in mesothelial cells. Am J Respir Cell Mol Biol 23:371–378CrossRefGoogle Scholar
  36. 36.
    Serio G, Pagliarulo V, Marzullo A, Punzi A, Pezzuto F (2016) Case report molecular changes of malignant mesothelioma in the testis and their impact on prognosis: analyses of two cases. Int J Clin Exp Pathol 9(7):7658–7667Google Scholar
  37. 37.
    Marsella JM, Liu BL, Vaslet CA, Kane AB (1997) Susceptibility of p53-deficient mice to induction of mesothelioma by crocidolite asbestos fibers. Environ Health Perspect 105(September):1069–1072PubMedPubMedCentralGoogle Scholar
  38. 38.
    de Reynies A, Jaurand M-C, Renier A et al (2014) Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition. Clin Cancer Res 20(5):1323–1335.  https://doi.org/10.1158/1078-0432.CCR-13-2429CrossRefPubMedGoogle Scholar
  39. 39.
    Chung CT, Da G, Santos C et al (2010) FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma. J Clin Pathol 63:630–634.  https://doi.org/10.1136/jcp.2010.076794CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Sarun KH, Lee K, Williams M et al (2018) Genomic deletion of BAP1 and CDKN2A are useful markers for quality control of malignant pleural mesothelioma (MPM) primary cultures. Int J Mol Sci 19:3056.  https://doi.org/10.3390/ijms19103056CrossRefPubMedCentralGoogle Scholar
  41. 41.
    Hylebos M, Van Camp G, Van Meerbeeck JP (2016) The genetic landscape of malignant pleural mesothelioma: results from massively parallel sequencing. J Thorac Oncol 11(10):1615–1626.  https://doi.org/10.1016/j.jtho.2016.05.020CrossRefPubMedGoogle Scholar
  42. 42.
    Yamaguchi R, Perkins G (2012) Finding a panacea among combination cancer therapies. Cancer Res 72(1):18–23.  https://doi.org/10.1158/0008-5472.CAN-11-3091CrossRefPubMedGoogle Scholar
  43. 43.
    Bruno R, Alì G, Giannini R et al (2017) Malignant pleural mesothelioma and mesothelial hyperplasia: a new molecular tool for the differential diagnosis. Oncotarget 8(2):2758–2770CrossRefGoogle Scholar
  44. 44.
    Parodi S, Filiberti R, Marroni P et al (2015) Differential diagnosis of pleural mesothelioma using logic learning machine. BMC Bioinformatics 16(Suppl 9):S3CrossRefGoogle Scholar
  45. 45.
    Tosun AB, Yergiyev O, Kolouri S, Silverman JF, Rohde GK (2015) Detection of malignant mesothelioma using nuclear structure of mesothelial cells in effusion cytology specimens. Cytometry A 87A:326–333.  https://doi.org/10.1002/cyto.a.22602CrossRefGoogle Scholar
  46. 46.
    Kundu S, Kolouri S, Erickson KI, Kramer AF, Rohde GK, May CV (2018) Discovery and visualization of structural biomarkers from MRI using transport-based morphometry. Neuroimage 167:256–275. arXiv:170504919v1CrossRefGoogle Scholar
  47. 47.
    Dozier J, Zheng H, Adusumilli PS (2017) Immunotherapy for malignant pleural mesothelioma: current status and future directions. Trans Lung Cancer 6(4):315–324.  https://doi.org/10.21037/tlcr.2017.05.02CrossRefGoogle Scholar
  48. 48.
    Milano MT, Zhang H (2010) Malignant pleural mesothelioma: a population-based study of survival. JTO Acquis 5(11):1841–1848.  https://doi.org/10.1097/JTO.0b013e3181f1cf2bCrossRefGoogle Scholar
  49. 49.
    Boutin C, Xey F, Gouvemet J et al (1993) Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients part 2: prognosis and staging. Cancer 72:394–404CrossRefGoogle Scholar
  50. 50.
    Minnema-Luiting J, Vroman H, Aerts J, Cornelissen R (2018) Heterogeneity in immune cell content in malignant pleural mesothelioma. Int J Mol Sci 19:1041.  https://doi.org/10.3390/ijms19041041CrossRefPubMedCentralGoogle Scholar
  51. 51.
    Varin E, Denoyelle C, Brotin E et al (2010) Downregulation of Bcl-x L and Mcl-1 is sufficient to induce cell death in mesothelioma cells highly refractory to conventional chemotherapy. Carcinogenesis 31(6):984–993.  https://doi.org/10.1093/carcin/bgq026CrossRefPubMedGoogle Scholar
  52. 52.
    Debrincat MA, Josefsson EC, James C et al (2012) Mcl-1 and Bcl-xL coordinately regulate megakaryocyte survival. Blood 119(24):5850–5858.  https://doi.org/10.1182/blood-2011-12-398834CrossRefPubMedGoogle Scholar
  53. 53.
    Yamaguchi R, Lartigue L, Perkins G (2019) Targeting Mcl-1 and other Bcl-2 family member proteins in cancer therapy. Pharmacol Ther 195:13–20CrossRefGoogle Scholar
  54. 54.
    Soini Y, Kinnula V, Kaarteenaho-wiik R, Apoptosis KE (1999) Expression of apoptosis regulating proteins bcl-2. Clin Cancer Res 5(November):3508–3515PubMedGoogle Scholar
  55. 55.
    Yamaguchi R, Perkins G, Hirota K (2015) Targeting cholesterol with beta-cyclodextrin sensitizes cancer cells for apoptosis. FEBS Lett 589:4097.  https://doi.org/10.1016/j.febslet.2015.11.009CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Ryuji Yamaguchi
    • 1
  • Guy Perkins
    • 2
  1. 1.JRC, Medical Research CompanyOsakaJapan
  2. 2.National Center for Microscopy and Imaging ResearchSchool of Medicine, University of CaliforniaSan Diego, La JollaUSA

Personalised recommendations